Piper Sandler reiterates Regeneron stock rating on anti-VEGF shift By Investing.com

Piper Sandler reiterated an Overweight rating on Regeneron with an $875 price target, about 17% above the current $747.74 share price, citing a structural shift away from Avastin that could unlock $3 billion to $3.5 billion in annual branded-market sales if utilization falls below 10%. The company also has several catalysts underway, including a U.S. pricing agreement, approval and rollout of its gene therapy Otarmeni, and a filed application for cemdisiran after positive Phase 3 data. Overall, the news is constructive for REGN, with multiple pipeline and strategic updates supporting the bullish analyst stance.

Analysis

The key read-through is not just incremental REGN upside, but a potential industry-level mix shift from commodity-like bevacizumab usage toward branded anti-VEGF pricing power. If community retina clinics are truly being squeezed on Avastin margins, the next leg of the trade is a volume reallocation that benefits the highest-trust branded franchises first, not necessarily the broadest basket of names. That creates asymmetric leverage for the incumbent with the strongest payer access and physician habit persistence, while also implying a smaller but real halo for adjacent branded ophthalmology suppliers.

The market is probably underestimating the duration of the transition. Once clinics retool workflows and billing around branded treatments, switching back is operationally hard, which makes the shift sticky over multiple quarters rather than a one-off quarter. The second-order effect is a widening moat for the branded leaders and a slower-than-expected erosion of pricing even if payer pushback intensifies, because the clinic economics—not just efficacy—appear to be driving adoption.

Near term, the main risk is that management commentary or payer interventions frame this as a temporary inventory or reimbursement artifact, which would compress the rerating quickly. The cleaner catalyst window is the upcoming earnings print and then the next 1-2 quarters of retina prescription data; if share gains are visible, sell-side targets likely move higher again. For TLX, the read-through is more selective: the partnership validates strategic optionality, but the stock only works if the market starts capitalizing platform value rather than treating collaborations as non-core.

Contrarianly, the consensus may be too focused on absolute upside to REGN and not enough on the broader category expansion. If Avastin share falls faster than expected, the biggest surprise could be that the pie grows through better reimbursement economics, allowing multiple branded participants to win simultaneously. The stock-specific opportunity is still best in REGN, but the broader trade is a relative-value long on branded anti-VEGF exposure versus any basket tied to low-margin off-label utilization.

Key Decisions for Investors

• Long REGN into earnings over the next 2-6 weeks; use the current setup for a momentum-plus-fundamental trade with ~2:1 upside/downside if retina share data confirm the mix shift.
• Buy REGN call spreads targeting the next quarterly print; the thesis is that any confirmation of sustained branded conversion will force another analyst estimate reset before the market fully prices it in.
• Pair trade: long REGN / short a basket of low-margin retina-utilization beneficiaries if identifiable in your coverage universe; this isolates mix-shift alpha from broader biotech beta.
• For TLX, treat the collaboration as a medium-term optionality catalyst rather than a near-term earnings driver; consider a small starter long only on pullbacks, with a 6-12 month horizon and limited position size.
• Set a stop/trim rule on REGN if management signals the Avastin decline is transitory or payer pushback emerges; that would challenge the core margin-expansion thesis within 1-2 quarters.